Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -5.12% is 86% above its 5-year average of -37.65%, near the high end of its 5-year range (-308.95%–12.91%).
27.82% below its 12-month average of -4.01%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -33.77%.
NET PROFIT MARGIN
-5.12%
NET PROFIT MARGIN AVG TTM
-4.01%
NET PROFIT MARGIN AVG 3Y
-19.88%
NET PROFIT MARGIN AVG 5Y
-37.65%
NET PROFIT MARGIN AVG 10Y
-533.98%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-27.82%
CURRENT VS 3Y AVG
+74.24%
CURRENT VS 5Y AVG
+86.40%
CURRENT VS 10Y AVG
+99.04%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-1362.86%
vs the sector median at left
Xeris Biopharma Holdings, Inc.
Market Cap
$1.74B
Net Profit Margin
-5.12%
TTM Avg
-4.01%
3Y Avg
-19.88%
5Y Avg
-37.65%
Market Cap
$1.74B
Net Profit Margin
-7756.37%
TTM Avg
-3193.87%
3Y Avg
-2536.69%
5Y Avg
-2093.05%
Market Cap
$1.74B
Net Profit Margin
0.89%
TTM Avg
-2.38%
3Y Avg
-5.83%
5Y Avg
-7.07%
Market Cap
$1.74B
Net Profit Margin
-21.25%
TTM Avg
-24.32%
3Y Avg
-26.63%
5Y Avg
-18.90%
Market Cap
$1.73B
Net Profit Margin
-672.16%
TTM Avg
-753.31%
3Y Avg
-935.73%
5Y Avg
-797.48%
Market Cap
$1.75B
Net Profit Margin
-2.63%
TTM Avg
-3.88%
3Y Avg
-2.58%
5Y Avg
-3.29%
Market Cap
$1.71B
Net Profit Margin
-153.84%
TTM Avg
-106.38%
3Y Avg
-133.58%
5Y Avg
-110.52%
Market Cap
$1.77B
Net Profit Margin
-636.99%
TTM Avg
-743.17%
3Y Avg
-743.17%
5Y Avg
-743.17%
Market Cap
$1.71B
Net Profit Margin
-14.99%
TTM Avg
-20.12%
3Y Avg
-16.95%
5Y Avg
-10.04%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | $1.74B | -5.12% | -4.01% | -19.88% | -37.65% |
| Absci Corporation (ABSI)vs › | $1.74B | -7756.37% | -3193.87% | -2536.69% | -2093.05% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 0.89% | -2.38% | -5.83% | -7.07% |
| Novocure Ltd (NVCR)vs › | $1.74B | -21.25% | -24.32% | -26.63% | -18.90% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | -672.16% | -753.31% | -935.73% | -797.48% |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | -2.63% | -3.88% | -2.58% | -3.29% |
| Personalis, Inc. (PSNL)vs › | $1.71B | -153.84% | -106.38% | -133.58% | -110.52% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | -636.99% | -743.17% | -743.17% | -743.17% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | -14.99% | -20.12% | -16.95% | -10.04% |
| Zenas BioPharma, Inc. (ZBIO)vs › | $1.70B | -48438.40% | -3458.57% | -1747.85% | -1747.85% |
Operating Margin
10.9%
Net Profit Margin
-5.1%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -33.77% |
| 2026-03-31 | 2.69% |
| 2025-12-31 | 12.91% |
| 2025-09-30 | 0.83% |
| 2025-06-30 | -2.70% |
| 2025-03-31 | -15.34% |
| 2024-12-31 | -8.51% |
| 2024-09-30 | -29.00% |
| 2024-06-30 | -31.22% |
| 2024-03-31 | -46.71% |
| 2023-12-31 | -30.16% |
| 2023-09-30 | -25.23% |
| 2023-06-30 | -52.20% |
| 2023-03-31 | -50.71% |
| 2022-12-31 | -39.01% |
| 2022-09-30 | -73.44% |
| 2022-06-30 | -103.47% |
| 2022-03-31 | -152.74% |
| 2021-12-31 | -234.39% |
| 2021-09-30 | -235.70% |
| 2021-06-30 | -308.95% |
| 2021-03-31 | -224.66% |
| 2020-12-31 | -304.75% |
| 2020-09-30 | -169.35% |
| 2020-06-30 | -1188.90% |
| 2020-03-31 | -1632.21% |
| 2019-12-31 | -1774.79% |
| 2019-09-30 | -10165.94% |
| 2019-06-30 | -10745.31% |
| 2019-03-31 | -10192.34% |
| 2018-12-31 | -2549.19% |
| 2018-09-30 | -2537.29% |
| 2018-06-30 | -1585.71% |
| 2018-03-31 | -4527.38% |
| 2017-12-31 | -1958.46% |
| 2017-09-30 | -4427.65% |
| 2017-06-30 | -926.02% |
| 2017-03-31 | -1313.28% |
